ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

maralixibat

Also written as “Maralixibat”, “LUM001” and “LUM001 (Maralixibat)”.

Its studies are mostly in Alagille Syndrome · Cholestasis, progressive familial intrahepatic 1 · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary · Intrahepatic Cholestasis of Pregnancy, led by 2 companies.

Drug pageMaralixibat: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 17, 202521 company-led studies, 3 open or runningNext primary completion: Jan 12, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mirum Pharmaceuticals193 open or runningphase 4since Sep 17, 2025Jul 16, 2013Jan 12, 2029phase 2 · NCT07823127
Takedaits history only20 open or runningphase 3since Sep 14, 2022Sep 14, 2022none ahead

Also a collaborator on its studies: Lumena Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mirum Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 16, 2013.

  1. Feb 5, 20143 phase 2 studiesNCT02057718, NCT02057692, NCT02061540
  2. Apr 16, 2014Phase 2 study in Alagille SyndromeNCT02117713 · 34 enrolled · United States, Canada
  3. Jun 9, 2014Phase 2 study in Alagille SyndromeNCT02160782 · 31 enrolled · Australia, Belgium, France and more
  4. Dec 12, 2014Phase 2 study in Liver Cirrhosis, BiliaryNCT02321306 · United States, United Kingdom
  5. Jun 10, 2015Phase 1 study in Healthy VolunteersNCT02475317 · 84 enrolled · United States
  6. Nov 14, 2017Phase 3 study in Cholestasis, progressive familial intrahepatic 1NCT03353454
  7. Apr 1, 2019Phase 3 study in Cholestasis, progressive familial intrahepatic 1NCT03905330 · 93 enrolled · United States, Argentina, Austria and more
  8. Oct 1, 2019Phase 2 study in Bile Duct DiseasesNCT04168385 · 52 enrolled · United States, Australia, Belgium and more
  9. Dec 2, 2019Phase 3 study in Cholestasis, progressive familial intrahepatic 1NCT04185363 · 84 enrolled · United States, Argentina, Austria and more
  10. Aug 20, 2020Phase 2 study in Biliary AtresiaNCT04524390 · 75 enrolled · United States, China, Germany and more
  11. Jan 25, 2021Phase 2 study in Cholestasis, progressive familial intrahepatic 1NCT04729751 · 27 enrolled · United States, Belgium, Brazil and more
  12. Aug 8, 2024Phase 3 study in Cholangitis, SclerosingNCT06553768 · 90 enrolled · United States, Brazil, Canada and more
  13. Sep 17, 2025Phase 4 study in Alagille SyndromeNCT07290257 · 230 planned · Belgium, France, Germany and more
  14. Aug 12, 2026Phase 2 study in Intrahepatic Cholestasis of PregnancyNCT07823127 · 15 planned

Ahead

  1. Jan 12, 2029Primary completion: phase 2 study in Intrahepatic Cholestasis of PregnancyNCT07823127
  2. Sep 22, 2030Primary completion: phase 4 study in Alagille SyndromeNCT07290257

TargetBeta

SLC10A2 →read by rule
“Ileal bile acid transporter inhibitor; Ileal bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A2

ProgramCompanyFurthest phaseStudies
linerixibatruleGlaxoSmithKlinephase 314

Studies

All 19 Mirum Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07823127Intrahepatic Cholestasis of Pregnancy2Not yet recruitingJan 12, 202915
NCT07290257Alagille Syndrome · Belgium, France, Germany and more4RecruitingSep 22, 2030230
NCT06553768Cholangitis, Sclerosing · United States, Brazil, Canada and more3Active, not recruitingJul 29, 202690
NCT04729751Cholestasis, progressive familial intrahepatic 1 · United States, Belgium, Brazil and more2CompletedDec 17, 202427
NCT04524390Biliary Atresia · United States, China, Germany and more2CompletedNov 7, 202375
NCT04185363Cholestasis, progressive familial intrahepatic 1 · United States, Argentina, Austria and more3CompletedApr 23, 202584
NCT04168385Bile Duct Diseases · United States, Australia, Belgium and more2CompletedSep 4, 202452
NCT03905330Cholestasis, progressive familial intrahepatic 1 · United States, Argentina, Austria and more3CompletedSep 1, 202293
NCT03353454Cholestasis, progressive familial intrahepatic 13WithdrawnJun 15, 20200
NCT02475317Healthy Volunteers · United States1CompletedDec 1, 201584
NCT02321306Liver Cirrhosis, Biliary · United States, United Kingdom2WithdrawnDec 20170
NCT02160782Alagille Syndrome · Australia, Belgium, France and more2CompletedMay 28, 202031
NCT02117713Alagille Syndrome · United States, Canada2CompletedJun 1, 202034
NCT02061540Cholangitis, Sclerosing · United States, Canada, United Kingdom2CompletedFeb 201627
NCT02057718Cholestasis, progressive familial intrahepatic 1 · United States, France, Poland and more2CompletedMay 8, 202033
NCT02057692Alagille Syndrome · United States, Canada2CompletedNov 16, 201637
NCT02047318Alagille Syndrome · United Kingdom2CompletedJun 17, 202019
NCT01904058Liver Cirrhosis, Biliary · United States, Canada, United Kingdom2CompletedApr 201566
NCT01903460Alagille Syndrome · United Kingdom2CompletedFeb 201520

How it is read

Names in the registry

  • “Maralixibat”, 9 entries
  • “LUM001”, 5 entries
  • “LUM001 (Maralixibat)”, 4 entries
  • “TAK-625”, 2 entries
  • “Livmarli Oral Product”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.